SCHEMBL21520161

SCHEMBL21520161

CC(C)(C)OC(=O)N1CCC[C@H]1C(=O)NCCc1ccc(C#N)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.52
CYP3A4 P08684 6/20 0.51
ERG P11308 6/20 0.51
GPBAR1 Q8TDU6 6/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
NPC1 O15118 1/20 0.50
CYP2C9 P11712 2/20 0.49
MAPT P10636 1/20 0.49
TSHR P16473 1/20 0.49
RAB9A P51151 1/20 0.49
LMNA P02545 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ATM Q13315 1/20 0.47
POLB P06746 1/20 0.47
FKBP1A P62942 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21520159 1.00 ALDH1A1 (0.52) ALDH1A1CYP3A4ERGGPBAR1SMN1; SMN2
SCHEMBL7049069 0.90 ALDH1A1 (0.59) ALDH1A1CYP3A4SMN1; SMN2NPC1CYP2C9
SCHEMBL28626848 0.88 ALDH1A1 (0.56) ALDH1A1CYP3A4SMN1; SMN2NPC1CYP2C9
SCHEMBL18257057 0.88 ALDH1A1 (0.56) ALDH1A1CYP3A4SMN1; SMN2NPC1CYP2C9
SCHEMBL28630307 0.88 LMNA (0.60) ALDH1A1CYP3A4SMN1; SMN2NPC1CYP2C9
SCHEMBL3931937 0.87 ALDH1A1 (0.56) ALDH1A1CYP3A4SMN1; SMN2NPC1CYP2C9
SCHEMBL28625164 0.87 ALDH1A1 (0.66) ALDH1A1CYP3A4SMN1; SMN2NPC1CYP2C9
SCHEMBL28622865 0.87 ALDH1A1 (0.55) ALDH1A1CYP3A4SMN1; SMN2NPC1CYP2C9
SCHEMBL28923360 0.87 ALDH1A1 (0.55) ALDH1A1CYP3A4SMN1; SMN2NPC1CYP2C9
SCHEMBL11096695 0.86 MEN1 (0.61) ALDH1A1CYP3A4SMN1; SMN2NPC1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654834-B2 Non-systemic TGR5 agonists Venenum Biodesign, LLC (US) 2020-05-19 US disclosed
US-10654834-B2 Non-systemic TGR5 agonists Venenum Biodesign, LLC (US) 2020-05-19 US disclosed
US-20190330191-A1 NOVEL NON-SYSTEMIC TGR5 AGONISTS Venenum Biodesign, LLC (US) 2019-10-31 US disclosed
US-20190330191-A1 NOVEL NON-SYSTEMIC TGR5 AGONISTS Venenum Biodesign, LLC (US) 2019-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190330191-A1 NOVEL NON-SYSTEMIC TGR5 AGONISTS GPR119, FFAR1, FFAR3 ALDH1A1 3170/4885CYP3A4 1581/4885ERG 4431/4885
US-10654834-B2 Non-systemic TGR5 agonists GPR119, SSTR5, FFAR3 ALDH1A1 3118/4885CYP3A4 1537/4885ERG 4475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.